Language: Spanish
References: 33
Page: 1-2
PDF size: 90.65 Kb.

Text Extraction

No abstract

REFERENCES

1. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents 1999-2000. JAMA 2002;288:1728-1732.

2. Strauss RS, Pollack HA. Epidemic increase childhood overweight, 1986-1998.

3. JAMA 2001;286:2845-2848.

4. Amigo H. Obesity in the Latin American children: situation, diagnostic criteria and challenges. Cad Saude Publica 2003; 19 (Supl 1): S1633-1670.

5. Hernández B, Peterson K, Sobol A, Rivera J, Sepúlveda J, Lezana MA. Obesity among 12-49 year-old women and children aged under five in Mexico. Salud Publica Mex 1996;38:178-188.

6. Del Río-Navarro BE, Velázquez-Monroy O, Sánchez-Castillo CP, Laura-Esqueda A, Berber A, Fanghanel G et al. The high prevalence of overweight and obesity in Mexican children. Obes Res 2004;12:215-223.

7. Departamento de Biología Molecular. Mecanismos moleculares de la resistencia bacteriana. Salud Publica Mex 1994; 36: 428-438.

8. Echániz-Avilés IG, Solórzano-Santos F. Meeting the challenge: Prevention of Pneumococcal disease with conjugate vaccines. Salud Publica Mex 2001;43:352-367.

9. Rodríguez RS, Calderón-Jaimes E, Gómez-Barreto D, Espinosa-de los Monteros LE. Características de la resistencia antimicrobiana de una colección clínica de Streptococcus pyogenes. Salud Publica Mex 2000; 42: 226-229.

10. Rivera-Tapia JA, Cedillo-Ramírez L, Vega-Benítez M. Micoplasmas y su importancia médica. Rev Biomed 2001; 12: 262-271.

11. Roberts MC, Koutsky LA, Holmes KK. LeBlane DJ, Kenny GE. Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences. Antimicrob Agents Chemother 1985; 28: 141-143.

12. Bebear CM, Renaudin H, Charron A, Gruson D, Lefrancos M, Bebear C. In vitro activity of trovafloxacina compared to those of five antimicrobials against mycoplasma including Mycoplasma hominis and Ureaplasma urealyticum fluorquinolone-resistant isolates that have been genetically characterized. Antimicrob Agents Chemother 2000; 44: 2557-2560.

13. Hannan PC, Woodnutt G. In vitro activity of gemifloxacin (SB 265805; LB 20304a) against human mycoplasma. J Antimicrob Chemother 2000; 45: 367-369.

14. Hannan PC. Antibiotic susceptibility of Mycoplasma fermentans strains from various sources and the development of resistance to aminoglycoside in vitro. J Med Microbiol 1995; 42: 421-428.

15. Hayes MM, Wear DJ, Lo SC. In vitro antimicrobial susceptibility testing for the newly identified AIDS-associated mycoplasma. Mycoplasma fermentans (incognitus strain). Arch Pathol Lab Med 1991;115: 464-466.

16. Pereyre S, Gonzalez P, de Barbeyrac B, Darnige A, Renaudin H, Charron A. Mutation in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in Mycoplasma hominis. Antimicrob Agents Chemother 2002; 46: 3142-3150.

17. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 375-382.

18. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents 1999-2000. JAMA 2002;288:1728-1732.

19. Strauss RS, Pollack HA. Epidemic increase childhood overweight, 1986-1998. JAMA 2001;286:2845-2848.

20. Amigo H. Obesity in the Latin American children: situation, diagnostic criteria and challenges. Cad Saude Publica 2003; 19 (Supl 1): S1633-1670.

21. Hernández B, Peterson K, Sobol A, Rivera J, Sepúlveda J, Lezana MA. Obesity among 12-49 year-old women and children aged under five in Mexico. Salud Publica Mex 1996;38:178-188.

22. Del Río-Navarro BE, Velázquez-Monroy O, Sánchez-Castillo CP, Laura-Esqueda A, Berber A, Fanghanel G et al. The high prevalence of overweight and obesity in Mexican children. Obes Res 2004;12:215-223.

23. Departamento de Biología Molecular. Mecanismos moleculares de la resistencia bacteriana. Salud Publica Mex 1994; 36: 428-438.

24. Echániz-Avilés IG, Solórzano-Santos F. Meeting the challenge: Prevention of Pneumococcal disease with conjugate vaccines. Salud Publica Mex 2001;43:352-367.

25. Rodríguez RS, Calderón-Jaimes E, Gómez-Barreto D, Espinosa-de los Monteros LE. Características de la resistencia antimicrobiana de una colección clínica de Streptococcus pyogenes. Salud Publica Mex 2000; 42: 226-229.

26. Rivera-Tapia JA, Cedillo-Ramírez L, Vega-Benítez M. Micoplasmas y su importancia médica. Rev Biomed 2001; 12: 262-271.

27. Roberts MC, Koutsky LA, Holmes KK. LeBlane DJ, Kenny GE. Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences. Antimicrob Agents Chemother 1985; 28: 141-143.

28. Bebear CM, Renaudin H, Charron A, Gruson D, Lefrancos M, Bebear C. In vitro activity of trovafloxacina compared to those of five antimicrobials against mycoplasma including Mycoplasma hominis and Ureaplasma urealyticum fluorquinolone-resistant isolates that have been genetically characterized. Antimicrob Agents Chemother 2000; 44: 2557-2560.

29. Hannan PC, Woodnutt G. In vitro activity of gemifloxacin (SB 265805; LB 20304a) against human mycoplasma. J Antimicrob Chemother 2000; 45: 367-369.

30. Hannan PC. Antibiotic susceptibility of Mycoplasma fermentans strains from various sources and the development of resistance to aminoglycoside in vitro. J Med Microbiol 1995; 42: 421-428.

31. Hayes MM, Wear DJ, Lo SC. In vitro antimicrobial susceptibility testing for the newly identified AIDS-associated mycoplasma. Mycoplasma fermentans (incognitus strain). Arch Pathol Lab Med 1991;115: 464-466.

32. Pereyre S, Gonzalez P, de Barbeyrac B, Darnige A, Renaudin H, Charron A. Mutation in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in Mycoplasma hominis. Antimicrob Agents Chemother 2002; 46: 3142-3150.

33. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 375-382.